ClinicalTrials.gg
Not yet recruitingNCT07692178Updated Jul 9, 2026

An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers

A Phase 2 interventional study of EX-03 in Venous Leg Ulcer (VLU), sponsored by MediWound Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by MediWound Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a pharmacokinetics (PK) study - the main objective of this study is to assess the PK, safety and clinical performance of 5% EscharEx (EX-03 formulation) in debridement of Venous Leg Ulcers

Read the detailed description

Approximately 20 eligible adult participants with VLU (with a surface area between 10 cm2 and 80 cm2, and wound age between 4 weeks and 2 Years), will be enrolled. The participants will be treated with EX-03 5%.

Each participant will go through 3 periods during the trial:

  • Screening period (2 visits, 7 (+3/-1) days apart),
  • Daily visits period (up to 8 daily site visits within up to 14 days), During the Daily visits period, Blood will be drawn for PK analysis before and after EscharEx application (i.e. during debridement treatment).

PK sampling will be obtained during and following applications of treatment at time points relative to the first application.

  • Weekly visits period (2 visits within 14 days), The overall duration of the study for a patient will be up to 5 weeks.
02

Conditions studied

  • Venous Leg Ulcer (VLU)

Browse trials for

Keywords

  • VLU
  • EscharEx
  • Debridement
  • Wound bed preparation
03

In context

Varicose Ulcer

370 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 308 interventional studies indexed under Varicose Ulcer.

Browse Varicose Ulcer studies →

Lead sponsor

MediWound Ltd is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women, older than 18 years of age,
  2. Participants with a VLU (determined by medical history, physical examination, and a documented ultrasound scan demonstrating venous insufficiency),
  3. Wound is present for at least 4 weeks but no longer than 2 years,
  4. The adherent necrotic/thick slough/fibrin non-viable tissue area, assessed following wound cleansing with wet gauze and either sterile saline or water and mild soap, is at least 50% of the wound area (assessed by clinical evaluation),
  5. Target wound surface area is in the range of 10-80 cm2 (assessed by eKare inSightTM),
  6. Participants understand the nature of the procedure, is able to adhere to the protocol regimen, and provides written prior to any study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Wound size that has decreased by > 20% after 7 (+3/-1) days of the screening period,
  2. Participants with more than one leg ulcer , on the leg of the target wound, with an area greater than or equal to 2 cm2, that are between 2 cm and 5 cm away from the edge of the target wound,
  3. Severely damaged skin (e.g., abrasion, erosion, exfoliation) extending >2 cm around the wound's edge,
  4. Signs of clinical infection of the wound or peri-wound, including purulent discharge, deep-tissue abscess, erysipelas, cellulitis, etc.,
  5. Presence of gangrene, signs of systemic infection, sepsis, or osteomyelitis during the screening phase,
  6. Clinical suspicion of skin cancer (e.g., basal cell carcinoma (BCC), squamous cell carcinoma (SCC), melanoma, or sarcoma), near the target wound, which was not ruled out by ,
  7. Participants with skin disorders unrelated to the wound that are present adjacent to the wound,
  8. Participants suffering from chronic skin disorders (Idiopathic Pruritus, Psoriasis, Panniculitis, Pyoderma Gangrenosum, etc.) that might deteriorate as a result of local trauma or debridement,
  9. Wound has sinus tracts or tunnels extending under healthy tissue, or penetrating into periosteum, fascia or bone,
  10. Participants with primary lymphatic edema (lymphedema),
  11. A significant decrease in the arterial blood flow of the extremity, as demonstrated by either Toe-Brachial Index (TBI) ≤ 0.50, Ankle-Brachial Index (ABI) ≤ 0.70, Skin Perfusion Pressure (SPP) ≤ 40 mmHg, Transcutaneous oximetry (TCOM) ≤ 40 mmHg, or lack of bi-phasic or tri-phasic doppler wave forms,
  12. Participants with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by silver sulfadiazine (SSD) pseudoeschar (i.e. pseudoeschar as a result of SSD treatment),
  13. History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,
  14. Participants with poor nutritional status: albumin \< 2.5g/dl, poorly controlled Diabetes Mellitus (for diabetic participants; > 12%), anemia (\<8 g/dL), a leukocyte counts \< 3,000/μl or >15000/μl, \<100,000/μl, abnormal liver function (, ALT>2 x ), renal failure (Cr > 2.5 mg/d or \< 30ml/min /1.73m2l ), >48,
  15. >2 or PTT > x 2 ULN (unless the patient receives coumarin derivatives anticoagulants (e.g. warfarin), and the INR and PTT levels are in their required levels and are stable),
  16. Participants undergoing renal or peritoneal dialysis,
  17. Any known condition that would preclude safe participation in the study, e.g., significant or unstable cardiac, vascular, pulmonary, liver, hematological, infectious, immunological, neoplastic disease, or any immediate life-threatening condition,
  18. Recent history or concurrent acute injury or disease that might compromise the patient's welfare, according to investigator discretion,
  19. The Patient is currently receiving, or has received within three months prior to enrollment, or is planned to receive during trial period, any medications or treatments known to affect the wound healing processes; these include chronic systemic intake or chronic systemic steroid intake with topical skin changes (i.e. thin, fragile skin with multiple hematomas or previous laceration history), immuno-suppressive drugs, immunomodulating medications, chemotherapy, and radiation therapy. Low and intermittent doses that the investigator determines as not for wound healing, may be permitted, provided that this determination is based on appropriate clinical judgment and is documented accordingly,
  20. Participants treated with Pentoxifylline within 2 weeks prior to screening,
  21. Venous ablation performed within the past month in an area adjacent to the target wound,
  22. Mentally incapacitated adults who are incapable of giving legal consent (e.g. dementia, psychiatric participants, etc.),
  23. Concurrent use of non-approved drugs or alcohol abuse,
  24. Pregnant women (positive pregnancy test) or nursing mothers
  25. Exposure to intervention within one month prior to enrollment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    EscharEx (EX-03)

    EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients. EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage.

    Drug: EX-03

Interventions

  • DrugEX-03

    a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the w

    Also known as: Gel vehicle, 5% EscharEx, EX-03 formulation

06

What researchers measure

Primary outcomes

  1. PK Evaluation

    Cmax (maximal observed serum concentration),

    Time frame: Up to 2 weeks

  2. Safety and Tolerability Endpoints

    Incidence and severity of systemic and local adverse events (AEs),

    Time frame: up to 5 weeks

  3. PK Evaluation

    AUC (area under the concentration -time curve)

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Incidence of complete debridement, clinically (visually) assessed after each application during the Daily Visits Period (up to 8 applications)

    counting events of complete debridement

    Time frame: up to 2 weeks

  2. Incidence of complete healthy viable granulation tissue, at the end of the Daily Visits Period, as assessed clinically

    counting events of complete granulation

    Time frame: up to 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
Jul 9, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07692178
Lead sponsor
MediWound Ltd
Collaborators
TFS HealthScience
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Shelly Vander
Contact
shellyv@mediwound.com
+972-523527960
Vered Sasson
Contact
vereds@mediwound.com
+972-546145559

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion